Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645-59. doi:10.1016/j.cell.2009.06.034.

Corsello SM, Roti G, Ross KN, et al. Identification of AML1-ETO modulators by chemical genomics. Blood. 2009;113(24):6193-205. doi:10.1182/blood-2008-07-166090.

Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68(10):3645-54. doi:10.1158/0008-5472.CAN-07-2938.

Chudnovsky Y, Kim D, Zheng S, et al. ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep. 2014;6(2):313-24. doi:10.1016/j.celrep.2013.12.032.

Kool M, Jones DTW, Jäger N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25(3):393-405. doi:10.1016/j.ccr.2014.02.004.

Del Vecchio CA, Feng Y, Sokol ES, et al. De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling. PLoS Biol. 2014;12(9):e1001945. doi:10.1371/journal.pbio.1001945.

Li W, Cavelti-Weder C, Zhang Y, et al. Long-term persistence and development of induced pancreatic beta cells generated by lineage conversion of acinar cells. Nat Biotechnol. 2014;32(12):1223-30. doi:10.1038/nbt.3082.

Riggi N, Knoechel B, Gillespie SM, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014;26(5):668-81. doi:10.1016/j.ccell.2014.10.004.

Liao J, Cui C. Generation and Characterization of Rat iPSCs. Methods Mol Biol. 2016;1357:133-48. doi:10.1007/7651_2015_200.

Kennedy AL, Vallurupalli M, Chen L, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015;6(30):30178-93. doi:10.18632/oncotarget.4903.